Skip to main content
AAPL+0.69%MSFT+0.96%GOOGL+1.78%NVDA+3.63%AMZN+1.69%SPCX+1.42%TSM+2.78%AVGO+2.47%META+1.21%TSLA+1.46%LLY+0.01%WMT+0.08%JPM-0.04%BRK-B0.00%V+0.01%SKHY0.00%AMD+3.30%MU+2.48%XOM0.00%JNJ+0.15%MA-0.02%ABBV+0.08%ASMLa-9.33%COST+0.19%1398.HK+0.25%KO+0.03%CVX+0.03%0700.HK-1.26%PG+0.09%CSCO+0.07%0939.HK0.00%HD+0.05%3988.HK-1.13%BAC+0.05%1816.HK+3.45%GE-0.03%0857.HK-0.49%ORCL-0.01%UNH+0.01%1288.HK-0.45%PM+0.02%0005.HK-3.08%NVS-0.01%HSBA.L-3.62%INTC+3.30%AZN-0.01%MS+0.02%RTX+0.02%ORp-0.36%TMO+0.14%GBPTRY+0.41%GBPHKD+0.32%GBPMXN-0.28%USDILS+0.16%USDCOP-0.04%PLNJPY0.00%GBPZAR0.00%USDZAR0.00%USDPLN0.00%EURNZD0.00%AUDCHF0.00%EURSEK0.00%GBPUSD0.00%GBPCHF0.00%USDDKK0.00%USDHKD0.00%GBPCAD0.00%NZDCAD0.00%GBPNZD0.00%GBPAUD0.00%EURCAD0.00%EURJPY0.00%EURNOK0.00%EURUSD0.00%CADCHF0.00%CADJPY0.00%CHFJPY0.00%NZDCHF0.00%NZDSGD0.00%EURCZK0.00%NOKJPY0.00%AUDCAD0.00%CHFSGD0.00%SGDJPY0.00%AUDSGD0.00%NZDUSD0.00%GBPJPY0.00%EURGBP0.00%AUDNZD0.00%AUDJPY0.00%AUDUSD0.00%USDJPY0.00%USDCNH0.00%EURCHF0.00%USDMXN0.00%USDNOK0.00%USDTHB0.00%USDTRY0.00%USDSEK0.00%USDCAD0.00%USDCHF0.00%EURHKD0.00%EURAUD0.00%AUDNOK0.00%EURCNH0.00%EURZAR0.00%EURSGD0.00%AUDDKK0.00%CHFSEK0.00%USDSGD0.00%EURPLN0.00%NZDJPY0.00%CHFNOK0.00%EURDKK0.00%NZDMXN0.00%GBPSGD0.00%GAGUSD0.00%W10.00%XAGUSD0.00%HG10.00%S10.00%C10.00%XNGUSD0.00%USOIL0.00%XAUUSD0.00%SUGAR0.00%COTTON0.00%COFFEE0.00%BTCUSD+1.22%ETHUSD+71.01%USDTUSD+0.12%XRPUSD+61.26%SOLUSD+68.72%TRXUSDT+0.17%ZECUSDT+2.43%XMRUSDT-0.23%DOGEUSD+69.80%LINKUSD+2.61%XLMUSD-0.91%BCHUSDT-0.75%LTCUSD+68.40%UNIUSD-0.56%TONUSD+79.92%SUIUSD+1.58%HBARUSDT-0.22%TAOUSDT+2.12%AAVEUSD+1.24%ONDOUSDT+0.94%DOTUSDT+1.46%ICPUSDT+2.37%WLDUSDT+3.32%ARBUSDT+1.96%ATOMUSDT+0.10%INJUSDT+3.96%STXUSDT+2.99%PYTHUSDT+4.45%TIAUSDT+2.74%FETUSDT+0.15%SEIUSDT+0.59%JUPUSDT+2.79%GRTUSDT+0.60%OPUSDT+1.55%IOTAUSDT+1.89%POLUSDT+0.30%WIFUSDT+1.51%AXSUSDT-0.15%EOSUSDT+0.52%IMXUSDT+0.09%FARTCOINUSDT+1.01%GALAUSDT+2.69%DYDXUSDT+0.09%ORDIUSDT+2.52%NOTUSDT+1.19%RONINUSDT+1.91%AAPL+0.69%MSFT+0.96%GOOGL+1.78%NVDA+3.63%AMZN+1.69%SPCX+1.42%TSM+2.78%AVGO+2.47%META+1.21%TSLA+1.46%LLY+0.01%WMT+0.08%JPM-0.04%BRK-B0.00%V+0.01%SKHY0.00%AMD+3.30%MU+2.48%XOM0.00%JNJ+0.15%MA-0.02%ABBV+0.08%ASMLa-9.33%COST+0.19%1398.HK+0.25%KO+0.03%CVX+0.03%0700.HK-1.26%PG+0.09%CSCO+0.07%0939.HK0.00%HD+0.05%3988.HK-1.13%BAC+0.05%1816.HK+3.45%GE-0.03%0857.HK-0.49%ORCL-0.01%UNH+0.01%1288.HK-0.45%PM+0.02%0005.HK-3.08%NVS-0.01%HSBA.L-3.62%INTC+3.30%AZN-0.01%MS+0.02%RTX+0.02%ORp-0.36%TMO+0.14%GBPTRY+0.41%GBPHKD+0.32%GBPMXN-0.28%USDILS+0.16%USDCOP-0.04%PLNJPY0.00%GBPZAR0.00%USDZAR0.00%USDPLN0.00%EURNZD0.00%AUDCHF0.00%EURSEK0.00%GBPUSD0.00%GBPCHF0.00%USDDKK0.00%USDHKD0.00%GBPCAD0.00%NZDCAD0.00%GBPNZD0.00%GBPAUD0.00%EURCAD0.00%EURJPY0.00%EURNOK0.00%EURUSD0.00%CADCHF0.00%CADJPY0.00%CHFJPY0.00%NZDCHF0.00%NZDSGD0.00%EURCZK0.00%NOKJPY0.00%AUDCAD0.00%CHFSGD0.00%SGDJPY0.00%AUDSGD0.00%NZDUSD0.00%GBPJPY0.00%EURGBP0.00%AUDNZD0.00%AUDJPY0.00%AUDUSD0.00%USDJPY0.00%USDCNH0.00%EURCHF0.00%USDMXN0.00%USDNOK0.00%USDTHB0.00%USDTRY0.00%USDSEK0.00%USDCAD0.00%USDCHF0.00%EURHKD0.00%EURAUD0.00%AUDNOK0.00%EURCNH0.00%EURZAR0.00%EURSGD0.00%AUDDKK0.00%CHFSEK0.00%USDSGD0.00%EURPLN0.00%NZDJPY0.00%CHFNOK0.00%EURDKK0.00%NZDMXN0.00%GBPSGD0.00%GAGUSD0.00%W10.00%XAGUSD0.00%HG10.00%S10.00%C10.00%XNGUSD0.00%USOIL0.00%XAUUSD0.00%SUGAR0.00%COTTON0.00%COFFEE0.00%BTCUSD+1.22%ETHUSD+71.01%USDTUSD+0.12%XRPUSD+61.26%SOLUSD+68.72%TRXUSDT+0.17%ZECUSDT+2.43%XMRUSDT-0.23%DOGEUSD+69.80%LINKUSD+2.61%XLMUSD-0.91%BCHUSDT-0.75%LTCUSD+68.40%UNIUSD-0.56%TONUSD+79.92%SUIUSD+1.58%HBARUSDT-0.22%TAOUSDT+2.12%AAVEUSD+1.24%ONDOUSDT+0.94%DOTUSDT+1.46%ICPUSDT+2.37%WLDUSDT+3.32%ARBUSDT+1.96%ATOMUSDT+0.10%INJUSDT+3.96%STXUSDT+2.99%PYTHUSDT+4.45%TIAUSDT+2.74%FETUSDT+0.15%SEIUSDT+0.59%JUPUSDT+2.79%GRTUSDT+0.60%OPUSDT+1.55%IOTAUSDT+1.89%POLUSDT+0.30%WIFUSDT+1.51%AXSUSDT-0.15%EOSUSDT+0.52%IMXUSDT+0.09%FARTCOINUSDT+1.01%GALAUSDT+2.69%DYDXUSDT+0.09%ORDIUSDT+2.52%NOTUSDT+1.19%RONINUSDT+1.91%
PT

Protagonist Therapeutics, Inc. (PTGX)

NASDAQ • Healthcare

$121.4
-$2.61 (-2.1%)
Market open

Last close at November 20, 2026 at 21:00 UTC

Open$123.41
Previous Close$121.4
Day Range$120.15 - $125.91
Avg. Volume (3M)582.9K
Market Cap$7.9B
P/E Ratio23.5
52 Week Range
$77$160.81

Metrics Over Time

Where the Money Goes

Q3 2026
Revenueeverything earned$274.4M100%
Gross Profitminus cost of goods$273.3M100%
Operating Incomeminus R&D and overhead$218.3M80%
Net Incomeminus taxes and the rest$220M80%

In plain terms: out of every $100 in revenue, Protagonist Therapeutics, Inc. keeps $80 as net profit.

Fundamentals & Financials

Revenue (TTM)
$551.6M
Net Income (TTM)
$342.2M
EPS (TTM)
$5.16
ROA (TTM)
29.85%
Current Ratio
19.85

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Earnings

+107.7%Q2 2026$0.05
+2.7%Q3 2026$2.29
+0.3%Q4 2026$3.07

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

Latest report — Q4 2026
Beat +0.3%

Based on preliminary results for Protagonist Therapeutics’ third fiscal quarter of 2026, reported November 5, 2026, the company posted a net loss, with EPS of -$0.32 and net income of roughly -$12.8 million, as it continued investing across its peptide-based pipeline spanning hematological and other blood disorders as well as inflammatory and immune-mediated diseases, including programs such as rusfertide (PTG-300), PN-943, and PN-235. With beat/miss comparisons not available for this release, results are best read through the bottom-line print and loss level rather than against consensus benchmarks for the reported period. Looking ahead, next-period consensus calls for EPS of -$0.32 on revenue of $35.3 million.

View full earnings history

About Protagonist Therapeutics, Inc.

Protagonist Therapeutics, Inc. is a NASDAQ-listed biotechnology company focused on discovering and advancing peptide-based therapies for blood, inflammatory, and immune-mediated disorders. The company develops clinical candidates across hematological and broader blood conditions as well as inflammatory disease, and generated $46.0 million of revenue in FY2025.

Name
Protagonist Therapeutics, Inc.
CEO
Dinesh V. Patel
Industry
Healthcare
Year Founded
2006
Employees
149

Today's Snapshot

AI-generated

PTGX closed 2.1% lower at 121.40, while its sector was flat.

Trading Volume

Above 10d avg 542.1K

593K

vs S&P 500 Today

Outperforming Market

+1.38%

Updated: November 20, 2026 at 21:09 UTC

Technical Indicators

2 Buy1 Neutral5 Sell
PTGX is showing a predominantly bearish technical posture as short- and medium-term moving averages sit above the current price while the 200-day averages remain just below, suggesting longer-term support amid shorter-term weakness. Momentum indicators are skewed negative — MACD and CCI are both signaling selling pressure even as RSI drifts toward oversold, and ADX around the mid-20s indicates a modestly persistent downtrend. Volume-based OBV is negative, and the classic pivot sits above price, reinforcing resistance. Volatility is moderate with an ATR near 4.7%. Technical takeaway: Sell.
All signals
  • EMA (5 indicators)$119.34 - $136.26
    Sell
  • RSI (14)31.51
    Neutral
  • Stochastic %K (14, 3, 3)12.19
    Buy
  • MACD Level (12, 26)-4.26
    Sell
Stay Ahead of the Market

Get premium market insights delivered directly to your inbox.